Corona Remedies Share Price Today (15 Dec 2025): Pharma Stock Debuts at 38% Premium After ₹655-Crore IPO — Latest News, Forecasts, Valuation and Analyst Views

New Delhi / Mumbai, December 15, 2025 — Corona Remedies Limited, the Ahmedabad-headquartered branded pharmaceutical formulations company (not the beer), hit Dalal Street with a headline-worthy debut on Monday: the stock listed at a 38%+ premium to its IPO price, quickly becoming one of the most-watched new names in India’s healthcare space. ^[1]

Below is a consolidated, publication-ready roundup of today’s key developments (15.12.2025) — including the latest price action, what the grey market had predicted, and how brokerages and IPO research notes are framing Corona Remedies’ valuation and outlook.

Corona Remedies stock news today: listing pop, intraday surge and market cap around ₹9,000 crore

Corona Remedies shares opened at ₹1,470 on NSE and ₹1,452 on BSE, versus the IPO issue price of ₹1,062, translating into a debut premium of roughly 38% (NSE) and 36.7% (BSE). ^[2]

The rally didn’t stop at the opening print. Multiple market updates through late morning/early afternoon showed the stock pushing up toward the ₹1,499 zone intraday (about 41% above the IPO price), underlining the intensity of day-one demand. ^[3]

By early afternoon, widely tracked market pages were indicating the share price hovering around the mid-₹1,460s to ₹1,470s and market capitalization around ~₹9,000 crore (figures vary slightly by timestamp and venue). ^[4]

A Reuters-breaking update distributed via TradingView also flagged heavy activity early in the session, citing trading volumes of millions of shares and valuing the company at roughly ₹90.25 billion (≈ ₹9,025 crore) at one snapshot. ^[5]

What Corona Remedies’ IPO “forecast” looked like — and why the stock beat it

Grey market premium: expected ~28–32% listing pop, actual ~38%

Ahead of listing day, the unofficial “grey market premium” (GMP) was signaling a strong but lower pop than what investors actually got.

A day-before listing check put GMP around ₹295, implying an indicative listing near ₹1,357 (about 28% over the top end of the price band). ^[6]
Other tracking estimates framed the likely listing gains closer to ~32%. ^[7]
A separate listing-day note from earlier in the IPO window cited a GMP around ₹270, pointing to ~₹1,332 as a possible listing level (about 25% over the upper band). ^[8]

Against those expectations, the actual market debut at ₹1,470 (NSE) was a clear “beat” versus the typical GMP-based forecast. ^[9]

Important reality check: GMP is not regulated, not a guarantee, and can swing on sentiment. Treat it like weather forecasting, not physics.

IPO details that mattered to investors on Day 1

Corona Remedies’ IPO was sized at ₹655.37 crore and structured as a 100% offer-for-sale (OFS) — meaning the company itself does not receive fresh capital from the issue; proceeds go to selling shareholders. ^[10]

Key identifiers investors are tracking now that the stock is live:

NSE symbol: CORONA
ISIN: INE02ZQ01018 ^[11]

Subscription: “blockbuster” is not hyperbole

On the demand front, the issue drew extraordinary interest, with reports pointing to overall subscription around 137x and exceptionally strong institutional bidding (QIB). ^[12]

(One major publication reported a somewhat higher overall figure around the mid-140s; the broad takeaway is the same: demand was extreme, especially from institutions.) ^[13]

What does Corona Remedies do, exactly?

Corona Remedies is an India-focused branded formulations pharmaceutical company operating across chronic and specialty therapy areas — with repeated emphasis across reports on women’s healthcare as a core franchise, alongside cardio-diabetes, pain management, urology, and other areas. ^[14]

IPO research from ICICI Direct describes:

A portfolio of 70+ brands
Two manufacturing facilities (Ahmedabad, Gujarat and Solan, Himachal Pradesh) with multiple production lines and dosage forms ^[15]

A separate IPO research note highlighted that roughly 70% of revenue is derived from chronic therapies, which typically come with higher prescription “stickiness” (patients staying on long-duration treatment regimens). ^[16]

Financial performance snapshot: fast growth, expanding margins

Several listing-day briefs reiterated a sharp improvement in profitability into FY25:

FY25 profit after tax cited around ₹149 crore, up sharply year-on-year, alongside revenue around ₹1,196–1,202 crore (minor variations appear by source and rounding). ^[17]
A recent quarterly profit figure around ₹46 crore on revenue around ₹346 crore was also cited in coverage. ^[18]

ICICI Direct’s IPO review additionally framed Corona’s FY23–FY25 as a period of strong acceleration, with FY25 EBITDA margin shown around ~20% in its summary table. ^[19]

Valuation and analyst views: “high-quality growth” vs “fully priced”

The market’s first-day enthusiasm doesn’t erase the central debate around Corona Remedies stock: how much is too much to pay for growth?

What brokerages/research notes are saying

NDTV Profit’s listing-day write-up summarized that multiple brokerages were generally favorable, highlighting Corona’s growth profile and operational efficiency — while also acknowledging the IPO valuation looked expensive by traditional measures. ^[20]
Choice Broking’s IPO report message is basically: strong growth + healthy margins, but valuation is fully priced — and still rated it “Subscribe for Long Term.” ^[21]
ICICI Direct’s IPO review computed valuation around ~44x P/E (and also cited EV/Sales and EV/EBITDA multiples), concluding that valuation looked expensive despite sound growth. ^[22]

Why you’ll see different P/E numbers floating around

A key reason valuation commentary varies is the earnings base used:

Some notes cite ~43–44x P/E around the upper IPO price band based on FY25 earnings. ^[23]
Another approach cited by The Economic Times used an annualised FY26 earnings lens and arrived at a lower multiple (mid-30s). ^[24]

Both can be “right” mathematically, but they imply different assumptions about how sustainable near-term earnings momentum is.

Post-listing strategy: what experts said investors should do next

Because Corona Remedies listed far above issue price, the first real decision point is no longer “apply or not,” but “hold, trim, or exit?”

A Moneycontrol listing-day piece quoted Swastika Investmart’s wealth desk suggesting a classic split approach: short-term investors may consider booking partial profits, while long-term investors could hold the balance if they’re comfortable with the company’s chronic-therapy positioning and steady operating profile. ^[25]

This is the sane middle path for a day-one winner: reduce regret risk (lock something in) without rage-quitting a business you actually want to own.

The big risks to watch now that Corona Remedies stock is in the wild

The first day is adrenaline. The next few quarters are the test. Here are the recurring risk themes highlighted in IPO research and market commentary:

Valuation risk: Multiple notes explicitly say the stock was not cheap even at the IPO price band; after a 35–40% pop, execution expectations rise further. ^[26]

Therapy concentration: ICICI Direct flagged concentration risk tied to major therapy areas contributing a large share of revenues. ^[27]

Third-party manufacturing dependence: Choice’s IPO note cited reliance on third-party manufacturers as a risk factor, and ICICI also flagged outsourcing exposure in its risk section. ^[28]

Pricing pressure / regulation: Like any India-focused formulations player, policy changes and price controls can matter; analysts explicitly mention pricing pressure as a key variable for longer-term returns. ^[29]

Margin sustainability: Several write-ups stress that longer-term returns hinge on defending margins and scaling brands without losing profitability. ^[30]

Bottom line: Corona Remedies stock starts life as a market favorite — now it has to earn the premium

Corona Remedies’ first day on the market delivered exactly what IPO buyers dream about: a strong listing premium, a push toward ~₹1,500 intraday, and a valuation that quickly moved toward ~₹9,000 crore territory. ^[31]

But the stock’s next chapter won’t be written by listing-day excitement. It will be written by:

sustained growth in its chronic therapy franchises,
the pace at which it can scale “engine brands,”
and whether earnings growth can keep up with a valuation that many analysts already called “fully priced” even before the pop. ^[32]